New treatment strategies and emerging drugs in endometriosis

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 83-104

  Streuli, Isabelle ^a,c   De Ziegler, Dominique ^a   Borghese, Bruno ^a   Santulli, Pietro ^a   Batteux, Frédéric ^a   Chapron, Charles ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT COCHIN   (France)

^c INSERM U1016 ^*  (France)

Author keywords

emerging drugs; endometriosis; hormonal treatment; infertility; medical treatment; non hormonal treatment; pain; surgical treatment

Indexed keywords

ABARELIX; ABT 620; ANASTROZOLE; AROMATASE INHIBITOR; ASOPRISNIL; ATORVASTATIN; BGS 649; BIOLOGICAL MARKER; CABERGOLINE; CETRORELIX; DANAZOL; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST; DIENOGEST PLUS ESTRADIOL VALERATE; ELAGOLIX; FULVESTRANT; GESTAGEN; GONADORELIN AGONIST; INFLIXIMAB; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OZARELIX; PENTOXIFYLLINE; PIOGLITAZONE; PRINABEREL; QUINAGOLIDE; RALOXIFENE; ROSIGLITAZONE; TANEZUMAB; TELAPRISTONE ACETATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOMYOSIS; CONSTIPATION; DEMOGRAPHY; DISEASE CLASSIFICATION; DRUG ACTIVITY; DYSMENORRHEA; DYSPAREUNIA; ENDOMETRIOSIS; ENDOMETRIUM BIOPSY; ENDOMETRIUM TUMOR; ENDOSCOPY; ENVIRONMENTAL FACTOR; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GENETIC RISK; HORMONAL THERAPY; HUMAN; INTRACELLULAR SIGNALING; LIFESTYLE; LOWER URINARY TRACT SYMPTOM; NUCLEAR MAGNETIC RESONANCE IMAGING; OVULATION; PELVIS LYMPH NODE; PELVIS PAIN SYNDROME; REVIEW; TRANSRECTAL ULTRASONOGRAPHY; TRANSVAGINAL ECHOGRAPHY;

EID: 84858981759     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.668885     Document Type: Review

References (172)

1. Bulun SE. Endometriosis. N Engl J Med 2009;360(3):268-79 Review on endometriosis and description of the feedback loop between inflammation and estrogens.
2. de Ziegler D, Borghese B, Chapron C. Endometriosis and infertility: pathophysiology and management. Lancet 2010;376(9742):730-8 Review on the mechanisms by which endometriosis leads to infertility and on the management of infertile women with endometriosis.
3. Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological evidence of the relationship and implications. Hum Reprod Update 2005;11(6):595-606 Review on the relationship between pain and endometriosis. (Pubitemid 41631309)
4. Sampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol 1927;3(2):93-110; 43
5. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24(2):235-58 (Pubitemid 27225159)
6. Simoens S, Hummelshoj L, D'Hooghe T. Endometriosis: cost estimates and methodological perspective. Hum Reprod Update 2007;13(4):395-404 (Pubitemid 47062831)
7. Chapron C, Pietin-Vialle C, Borghese B, et al. Associated ovarian endometrioma is a marker for greater severity of deeply infiltrating endometriosis. Fertil Steril 2009;92(2):453-7
8. Chapron C, Bourret A, Chopin N, et al. Surgery for bladder endometriosis: long-term results and concomitant management of associated posterior deep lesions. Hum Reprod 2010;25(4):884-9
9. Koninckx PR, Meuleman C, Demeyere S, et al. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 1991;55(4):759-65
10. Chapron C, Chopin N, Borghese B, et al. Deeply infiltrating endometriosis: pathogenetic implications of the anatomical distribution. Hum Reprod 2006;21(7):1839-45 (Pubitemid 44028259)
11. Bricou A, Batt RE, Chapron C. Peritoneal fluid flow influences anatomical distribution of endometriotic lesions: why Sampson seems to be right. Eur J Obstet Gynecol Reprod Biol 2008;138(2):127-34 (Pubitemid 351735940)
12. Abrao MS, Podgaec S, Dias JA Jr, et al. Deeply infiltrating endometriosis affecting the rectum and lymph nodes. Fertil Steril 2006;86(3):543-7 (Pubitemid 44307031)
13. Noel JC, Chapron C, Fayt I, et al. Lymph node involvement and lymphovascular invasion in deep infiltrating rectosigmoid endometriosis. Fertil Steril 2008;89(5):1069-72 (Pubitemid 351671720)
14. Signorile PG, Baldi A. Endometriosis: new concepts in the pathogenesis. Int J Biochem Cell Biol 2010;42(6):778-80
15. Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod 2009;24(3):496-501
16. Abrao MS, Goncalves MO, Dias JA Jr, et al. Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis. Hum Reprod 2007;22(12):3092-7 (Pubitemid 351696760)
17. Piketty M, Chopin N, Dousset B, et al. Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal ultrasonography must definitely be the first-line imaging examination. Hum Reprod 2009;24(3):602-7
18. Rogers PA, D'Hooghe TM, Fazleabas A, et al. Priorities for endometriosis research: recommendations from an international consensus workshop. Reprod Sci 2009;16(4):335-46
19. Somigliana E, Vercellini P, Vigano P, et al. Non-invasive diagnosis of endometriosis: the goal or own goal? Hum Reprod 2010;25(8):1863-8
20. Mihalyi A, Gevaert O, Kyama CM, et al. Non-invasive diagnosis of endometriosis based on a combined analysis of six plasma biomarkers. Hum Reprod 2010;25(3):654-64
21. Brosens IA. Endometriosis - a disease because it is characterized by bleeding. Am J Obstet Gynecol 1997;176(2):263-7 (Pubitemid 27107906)
22. Vercellini P. Endometriosis: what a pain it is. Semin Reprod Endocrinol 1997;15(3):251-61 (Pubitemid 27500173)
23. Anaf V, Simon P, El Nakadi I, et al. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000;15(8):1744-50 (Pubitemid 30636063)
24. Vercellini P, Crosignani PG, Somigliana E, et al. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod 2009;24(10):2504-14 Review on medical treatments for deep infiltrating endometriosis.
25. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;10(10):2698-704 ESHRE endometriosis guidelines. (Pubitemid 41487622)
26. Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet 2012;285(1):167-73
27. Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod 2010;25(3):633-41
28. Strowitzki T, Faustmann T, Gerlinger C, et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010;151(2):193-829.
29. Vercellini P, Pietropaolo G, De Giorgi O, et al. Reproductive performance in infertile women with rectovaginal endometriosis: is surgery worthwhile? Am J Obstet Gynecol 2006;195(5):1303-10
30. Vercellini P, Crosignani PG, Abbiati A, et al. The effect of surgery for symptomatic endometriosis: the other side of the story. Hum Reprod Update 2009;15(2):177-88
31. Dousset B, Leconte M, Borghese B, et al. Complete surgery for low rectal endometriosis: long-term results of a 100-case prospective study. Ann Surg 2010;251(5):887-95
32. Cheong Y, Tay P, Luk F, et al. Laparoscopic surgery for endometriosis: how often do we need to re-operate? J Obstet Gynaecol 2008;28(1):82-5 (Pubitemid 351220613)
33. Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004;16(4):299-303 (Pubitemid 41015800)
34. Somigliana E, Chiodini A, Odorizzi MP, et al. The therapy of endometriosis. New prospects. Minerva Ginecol 2003;55(1):15-23
35. Weir E, Mustard C, Cohen M, et al. Endometriosis: what is the risk of hospital admission, readmission, and major surgical intervention? J Minim Invasive Gynecol 2005;12(6):486-93 (Pubitemid 41758422)
36. Vignali M, Bianchi S, Candiani M, et al. Surgical treatment of deep endometriosis and risk of recurrence. J Minim Invasive Gynecol 2005;12(6):508-13 (Pubitemid 41758425)
37. Hachisuga T, Kawarabayashi T. Histopathological analysis of laparoscopically treated ovarian endometriotic cysts with special reference to loss of follicles. Hum Reprod 2002;17(2):432-5 (Pubitemid 34168453)
38. Hirokawa W, Iwase A, Goto M, et al. The post-operative decline in serum anti-Mullerian hormone correlates with the bilaterality and severity of endometriosis. Hum Reprod 2011;26(4):904-10
39. Somigliana E, Ragni G, Benedetti F, et al. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. Hum Reprod 2003;18(11):2450-3 (Pubitemid 37427830)
40. May KE, Villar J, Kirtley S, et al. Endometrial alterations in endometriosis: a systematic review of putative biomarkers. Hum Reprod Update 2011;17(5):637-53
41. Fedele L, Parazzini F, Radici E, et al. Buserelin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: a randomized clinical trial. Am J Obstet Gynecol 1992;166(5):1345-50
42. Fedele L, Bianchi S, Arcaini L, et al. Buserelin versus danazol in the treatment of endometriosis-associated infertility. Am J Obstet Gynecol 1989;161(4):871-6 (Pubitemid 19266187)
43. Fraser IS, Shearman RP, Jansen RP, et al. A comparative treatment trial of endometriosis using the gonadotrophin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol 1991;31(2):158-63
44. Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med 1988;318(8):485-9 (Pubitemid 18054295)
45. Rotondi M, Labriola D, Ammaturo FP, et al. Depot leuprorelin acetate versus danazol in the treatment of infertile women with symptomatic endometriosis. Eur J Gynaecol Oncol 2002;23(6):523-6 (Pubitemid 36069995)
46. Busacca M, Somigliana E, Bianchi S, et al. Post-operative GnRH analogue treatment after conservative surgery for symptomatic endometriosis stage III-IV: a randomized controlled trial. Hum Reprod 2001;16(11):2399-402 (Pubitemid 33054145)
47. Loverro G, Carriero C, Rossi AC, et al. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. Eur J Obstet Gynecol Reprod Biol 2008;136(2):194-8 (Pubitemid 351173441)
48. Parazzini F, Fedele L, Busacca M, et al. Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial. Am J Obstet Gynecol 1994;171(5):1205-7 (Pubitemid 24365716)
49. Vercellini P, Crosignani PG, Fadini R, et al. A gonadotrophin-releasing hormone agonist compared with expectant management after conservative surgery for symptomatic endometriosis. Br J Obstet Gynaecol 1999;106(7):672-7 (Pubitemid 29304389)
50. Dicker D, Goldman JA, Levy T, et al. The impact of long-term gonadotropin-releasing hormone analogue treatment on preclinical abortions in patients with severe endometriosis undergoing in vitro fertilization-embryo transfer. Fertil Steril 1992;57(3):597-600
51. Rickes D, Nickel I, Kropf S, et al. Increased pregnancy rates after ultralong postoperative therapy with gonadotropin-releasing hormone analogs in patients with endometriosis. Fertil Steril 2002;78(4):757-62
52. Sallam HN, Garcia-Velasco JA, Dias S, et al. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev 2006(1):CD004635
53. Surrey ES, Silverberg KM, Surrey MW, et al. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril 2002;78(4):699-704
54. de Ziegler D, Gayet V, Aubriot FX, et al. Use of oral contraceptives in women with endometriosis before assisted reproduction treatment improves outcomes. Fertil Steril 2010;94(7):2796-9
55. Vercellini P, Somigliana E, Vigano P, et al. Surgery for endometriosis-associated infertility: a pragmatic approach. Hum Reprod 2009;24(2):254-69
56. Vercellini P, Fedele L, Aimi G, et al. Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: the predictive value of the current classification system. Hum Reprod 2006;21(10):2679-85 (Pubitemid 44542163)
57. De Ziegler D, Streuli MI, Borghese B, et al. Infertility and endometriosis: a need for global management that optimizes the indications for surgery and ART. Minerva Ginecol 2011;63(4):365-73
58. Somigliana E, Infantino M, Benedetti F, et al. The presence of ovarian endometriomas is associated with a reduced responsiveness to gonadotropins. Fertil Steril 2006;86(1):192-6 (Pubitemid 43977764)
59. Somigliana E, Vercellini P, Vigano P, et al. Should endometriomas be treated before IVF-ICSI cycles? Hum Reprod Update 2006;12(1):57-64 (Pubitemid 43013747)
60. Zondervan KT, Yudkin PL, Vessey MP, et al. Prevalence and incidence of chronicpelvic pain in primary care: evidence from a national general practice database. Br J Obstet Gynaecol 1999;106(11):1149-55 (Pubitemid 29495414)
61. Kyama MC, D'Hooghe TM, Debrock S, et al. The prevalence of endometriosis among African-American and African-indigenous women. Gynecol Obstet Invest 2004;57(1):40-2 (Pubitemid 38186429)
62. Vigano P, Parazzini F, Somigliana E, et al. Endometriosis: epidemiology and aetiological factors. Best Pract Res Clin Obstet Gynaecol 2004;18(2):177-200 (Pubitemid 38786627)
63. Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997;10(4):199-202 (Pubitemid 27523730)
64. Gao X, Outley J, Botteman M, et al. Economic burden of endometriosis. Fertil Steril 2006;86(6):1561-72
65. Kunz K KM, Moynihan C, Williamson A, Mazonson P. The cost of treatment of endometriosisin the California Medicaid population. Am J Manag Care 1995(1):25-9
66. Available from: www.globaldata.com
67. Available from: www.prnewswire.com
68. Pipeline Insight: Endometriosis- New therapies near market while more innovative targets still needed, executive summary. Available from: www. datamonitor.com; 10.12.2009:Chapter 1
69. Chapron C, Borghese B, Streuli I, et al. Markers of adult endometriosis detectable in adolescence. J Pediatr Adolesc Gynecol 2011;24(5 Suppl):S7-12 Discussion about new strategies that should be developed for the management of adolescents with pelvic pain.
70. Chapron C, Souza C, Borghese B, et al. Oral contraceptives and endometriosis: the past use of oral contraceptives for treating severe primary dysmenorrhea is associated with endometriosis, especially deep infiltrating endometriosis. Hum Reprod 2011;26(8):2028-35
71. Chapron C, Lafay-Pillet MC, Monceau E, et al. Questioning patients about their adolescent history can identify markers associated with deep infiltrating endometriosis. Fertil Steril 2011;95(3):877-81
72. Treloar SA, Bell TA, Nagle CM, et al. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol 2010;202(6):534; e1-6
73. Martinez-Conejero JA, Morgan M, Montesinos M, et al. Adenomyosis does not affect implantation, but is associated with miscarriage in patients undergoing oocyte donation. Fertil Steril 2011;96(4):943-50
74. Maubon A, Faury A, Kapella M, et al. Uterine junctional zone at magnetic resonance imaging: a predictor of in vitro fertilization implantation failure. J Obstet Gynaecol Res 2010;36(3):611-18
75. Bulun SE, Sharda G, Rink J, et al. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J Clin Endocrinol Metab 1996;81(3):1273-7 (Pubitemid 26084463)
76. Colette S, Lousse JC, Defrere S, et al. Absence of aromatase protein and mRNA expression in endometriosis. Hum Reprod 2009;24(9):2133-41
77. Colette S, Donnez J. Are aromatase inhibitors effective in endometriosis treatment? Expert Opin Investig Drugs 2011;20(7):917-31 Review on aromatase inhibitors in endometriosis.
78. Lossl K, Loft A, Freiesleben NL, et al. Combined down-regulation by aromatase inhibitor and GnRH-agonist in IVF patients with endometriomas-A pilot study. Eur J Obstet Gynecol Reprod Biol 2009;144(1):48-53
79. Soysal S, Soysal ME, Ozer S, et al. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 2004;19(1):160-7 (Pubitemid 38072026)
80. Alborzi S, Hamedi B, Omidvar A, et al. A comparison of the effect of short-term aromatase inhibitor (letrozole) and GnRH agonist (triptorelin) versus case control on pregnancy rate and symptom and sign recurrence after laparoscopic treatment of endometriosis. Arch Gynecol Obstet 2011;284(1):105-10
81. Available from: www.ClinicalTrials.gov [Accessed on December 2011] Web site of registered clinical trials.
82. Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab 2009;94(2):545-51
83. Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96(5):1175-89
84. Gopalkrishnan K, Katkam RR, Sachdeva G, et al. Effects of an antiprogestin onapristone on the endometrium of bonnet monkeys: morphometric and ultrastructural studies. Biol Reprod 2003;68(6):1959-67 (Pubitemid 36686985)
85. Brenner RM, Slayden OD, Nath A, et al. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2010;81(4):336-42
86. Grow DR, Williams RF, Hsiu JG, et al. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81(5):1933-9 (Pubitemid 26152488)
87. Kettel LM, Murphy AA, Morales AJ, et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil Steril 1996;65(1):23-8 (Pubitemid 26006643)
88. Kettel LM, Murphy AA, Morales AJ, et al. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178(6):1151-6 (Pubitemid 28304614)
89. Clarke BL, Khosla S. New selective estrogen and androgen receptor modulators. Curr Opin Rheumatol 2009;21(4):374-9
90. Buelke-Sam J, Bryant HU, Francis PC. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol 1998;12(3):217-21 (Pubitemid 29110885)
91. Yao Z, Shen X, Capodanno I, et al. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. J Invest Surg 2005;18(4):177-83 (Pubitemid 41200609)
92. Stratton P, Sinaii N, Segars J, et al. Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. Obstet Gynecol 2008;111(1):88-9693.
93. Guo SW, Olive DL. Two unsuccessful clinical trials on endometriosis and a few lessons learned. Gynecol Obstet Invest 2007;64(1):24-35
94. Brandenberger AW, Lebovic DI, Tee MK, et al. Oestrogen receptor (ER)- alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod 1999;5(7):651-5 (Pubitemid 29317755)
95. Cavallini A, Resta L, Caringella AM, et al. Involvement of estrogen receptor-related receptors in human ovarian endometriosis. Fertil Steril 2011;96(1):102-6
96. Bukulmez O, Hardy DB, Carr BR, et al. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology 2008;149(3):1190-204 (Pubitemid 351397966)
97. Harris HA, Bruner-Tran KL, Zhang X, et al. A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Hum Reprod 2005;20(4):936-41 (Pubitemid 40667838)
98. Nap AW, Griffioen AW, Dunselman GA, et al. Antiangiogenesis therapy for endometriosis. J Clin Endocrinol Metab 2004;89(3):1089-95 (Pubitemid 38368395)
99. Nisolle M, Casanas-Roux F, Anaf V, et al. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59(3):681-4 (Pubitemid 23086336)
100. McLaren J, Prentice A, Charnock-Jones DS, et al. Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. Hum Reprod 1996;11(1):220-3 (Pubitemid 26047702)
101. McLaren J, Prentice A, Charnock-Jones DS, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J Clin Invest 1996;98(2):482-9 (Pubitemid 26255749)
102. Taylor RN, Yu J, Torres PB, et al. Mechanistic and therapeutic implications of angiogenesis in endometriosis. Reprod Sci 2009;16(2):140-6
103. Machado DE, Abrao MS, Berardo PT, et al. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008;90(1):148-55 (Pubitemid 351885185)
104. Ricci AG, Olivares CN, Bilotas MA, et al. Effect of vascular endothelial growth factor inhibition on endometrial implant development in a murine model of endometriosis. Reprod Sci 2011;18(7):614-22
105. Novella-Maestre E, Carda C, Noguera I, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Hum Reprod 2009;24(5):1025-35
106. Delgado-Rosas F, Gomez R, Ferrero H, et al. The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis. Reproduction 2011;142(5):745-55
107. Barlier A, Jaquet P. Quinagolide - a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 2006;154(2):187-95
108. dos Santos Nunes V, El Dib R, Boguszewski CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pituitary 2011;14(3):259-65
109. Stalldecker G, Mallea-Gil MS, Guitelman M, et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010;13(4):345-50
110. Valassi E, Klibanski A, Biller BM. Clinical Review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010;95(3):1025-33
111. Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356(1):39-46 (Pubitemid 46041752)
112. Gomez R, Abad A, Delgado F, et al. Effects of hyperprolactinemia treatment with the dopamine agonist quinagolide on endometriotic lesions in patients with endometriosis-associated hyperprolactinemia. Fertil Steril 2011;95(3):882-8; e1
113. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab 2009;94(7):2489-94
114. Esfandiari N, Khazaei M, Ai J, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril 2007;87(2):257-62 (Pubitemid 46188442)
115. Yilmaz B, Ozat M, Kilic S, et al. Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online 2010;20(2):291-9
116. Bedaiwy MA, Falcone T, Sharma RK, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod 2002;17(2):426-31 (Pubitemid 34168452)
117. Richter ON, Dorn C, Rosing B, et al. Tumor necrosis factor alpha secretion by peritoneal macrophages in patients with endometriosis. Arch Gynecol Obstet 2005;271(2):143-7 (Pubitemid 40476246)
118. Hill JA, Haimovici F, Anderson DJ. Products of activated lymphocytes and macrophages inhibit mouse embryo development in vitro. J Immunol 1987;139(7):2250-4 (Pubitemid 17152118)
119. Falconer H, Mwenda JM, Chai DC, et al. Treatment with anti-TNF monoclonal antibody (c5N) reduces the extent of induced endometriosis in the baboon. Hum Reprod 2006;21(7):1856-62 (Pubitemid 44028261)
120. D'Hooghe TM, Nugent NP, Cuneo S, et al. Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod 2006;74(1):131-6 (Pubitemid 43068800)
121. Koninckx PR, Craessaerts M, Timmerman D, et al. Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 2008;23(9):2017-23
122. Guo SW. Emerging drugs for endometriosis. Expert Opin Emerg Drugs 2008;13(4):547-71
123. Lv D, Song H, Li Y, et al. Pentoxifylline versus medical therapies for subfertile women with endometriosis. Cochrane Database Syst Rev 2009(3):CD007677124.
124. Marques LJ, Zheng L, Poulakis N, et al. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med 1999;159(2):508-11
125. Nothnick WB, Curry TE, Vernon MW. Immunomodulation of rat endometriotic implant growth and protein production. Am J Reprod Immunol 1994;31(2-3):151-62 (Pubitemid 24149361)
126. Steinleitner A, Lambert H, Suarez M, et al. Immunomodulation in the treatment of endometriosis-associated subfertility: use of pentoxifylline to reverse the inhibition of fertilization by surgically induced endometriosis in a rodent model. Fertil Steril 1991;56(5):975-9
127. Steinleitner A, Lambert H, Roy S. Immunomodulation with pentoxifylline abrogates macrophage-mediated infertility in an in vivo model: a paradigm for a novel approach to the treatment of endometriosis-associated subfertility. Fertil Steril 1991;55(1):26-31
128. Alborzi S, Ghotbi S, Parsanezhad ME, et al. Pentoxifylline therapy after laparoscopic surgery for different stages of endometriosis: a prospective, double-blind, randomized, placebo-controlled study. J Minim Invasive Gynecol 2007;14(1):54-8 (Pubitemid 46049099)
129. Balasch J, Creus M, Fabregues F, et al. Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial. Hum Reprod 1997;12(9):2046-50
130. Creus M, Fabregues F, Carmona F, et al. Combined laparoscopic surgery and pentoxifylline therapy for treatment of endometriosis-associated infertility: a preliminary trial. Hum Reprod 2008;23(8):1910-16 (Pubitemid 352020005)
131. Kamencic H, Thiel JA. Pentoxifylline after conservative surgery for endometriosis: a randomized, controlled trial. J Minim Invasive Gynecol 2008;15(1):62-6 (Pubitemid 351199832)
132. Olivares C, Ricci A, Bilotas M, et al. The inhibitory effect of celecoxib and rosiglitazone on experimental endometriosis. Fertil Steril 2011;96(2):428-33
133. Sharma I, Dhawan V, Saha SC, et al. In vitro effects of peroxisome proliferator-activated receptor-gamma ligands on gene expression in lipopolysaccharide-induced endometrial and endometriotic stromal cells. Fertil Steril 2011;95(2):829-31; e1-5
134. Nissen SE. Perspective: effect of rosiglitazone on cardiovascular outcomes. Curr Cardiol Rep 2007;9(5):343-4 (Pubitemid 47365132)
135. Peeters LL, Vigne JL, Tee MK, et al. PPAR gamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 2005;8(4):373-9
136. Lebovic DI, Mwenda JM, Chai DC, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007;88(4 Suppl):1108-19 (Pubitemid 47520613)
137. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71 (Pubitemid 46919772)
138. Borghese B, Vaiman D, Mondon F, et al. Neurotrophins and pain in endometriosis. Gynecol Obstet Fertil 2010;38(7-8):442-6
139. Bulun SE, Cheng YH, Pavone ME, et al. Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med 2010;28(1):36-43
140. Boonyaratanakornkit V. Scaffolding proteins mediating membrane-initiated extra-nuclear actions of estrogen receptor. Steroids 2011;76(9):877-84
141. Lu Q, Pallas DC, Surks HK, et al. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci USA 2004;101(49):17126-31 (Pubitemid 39627785)
142. Leconte M, Nicco C, Ngo C, et al. Antiproliferative effects of cannabinoid agonists on deep infiltrating endometriosis. Am J Pathol 2010;177(6):2963-70
143. Leconte M, Nicco C, Ngo C, et al. The mTOR/AKT inhibitor temsirolimus prevents deep infiltrating endometriosis in mice. Am J Pathol 2011;179(2):880-9
144. Ngo C, Chereau C, Nicco C, et al. Reactive oxygen species controls endometriosis progression. Am J Pathol 2009;175(1):225-34
145. Halme J, Becker S, Haskill S. Altered maturation and function of peritoneal macrophages: possible role in pathogenesis of endometriosis. Am J Obstet Gynecol 1987;156(4):783-9 (Pubitemid 17058777)
146. Halme J, White C, Kauma S, et al. Peritoneal macrophages from patients with endometriosis release growth factor activity in vitro. J Clin Endocrinol Metab 1988;66(5):1044-9
147. Ngo C, Nicco C, Leconte M, et al. Protein kinase inhibitors can control the progression of endometriosis in vitro and in vivo. J Pathol 2010;222(2):148-57
148. Tang L, Wang TT, Wu YT, et al. High expression levels of cyclin B1 and Polo-like kinase 1 in ectopic endometrial cells associated with abnormal cell cycle regulation of endometriosis. Fertil Steril 2009;91(4):979-87
149. Ngo C, Nicco C, Leconte M, et al. Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo. Fertil Steril 2010;94(5):1632-8; e1
150. Wang Y, Sharma RK, Falcone T, et al. Importance of reactive oxygen species in the peritoneal fluid of women with endometriosis or idiopathic infertility. Fertil Steril 1997;68(5):826-30 (Pubitemid 27506095)
151. Batteux F, Kavian N, Servettaz A. New insights on chemically induced animal models of systemic sclerosis. Curr Opin Rheumatol 2011;23(6):511-18
152. Dooley A, Bruckdorfer KR, Abraham DJ. Modulation of fibrosis in systemic sclerosis by nitric oxide and antioxidants. Cardiol Res Pract 2012;2012:521958
153. Anaf V, Simon P, Fayt I, et al. Smooth muscles are frequent components of endometriotic lesions. Hum Reprod 2000;15(4):767-71 (Pubitemid 30192720)
154. Yoshino O, Osuga Y, Hirota Y, et al. Possible pathophysiological roles of mitogen-activated protein kinases (MAPKs) in endometriosis. Am J Reprod Immunol 2004;52(5):306-11 (Pubitemid 39585717)
155. Yotova IY, Quan P, Leditznig N, et al. Abnormal activation of Ras/Raf/MAPK and RhoA/ROCKII signalling pathways in eutopic endometrial stromal cells of patients with endometriosis. Hum Reprod 2011;26(4):885-97
156. Chang RJ, Laufer LR, Meldrum DR, et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin- releasinghormone agonist. J Clin Endocrinol Metab 1983;56(5):897-903 (Pubitemid 13135164)
157. Meldrum DR, Chang RJ. Lu J, et al. "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 1982;54(5):1081-3 (Pubitemid 13243727)
158. Steingold KA, Cedars M, Lu JK, et al. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol 1987;69(3 Pt 1):403-11 (Pubitemid 17027477)
159. Schriock E, Monroe SE, Henzl M, et al. Treatment of endometriosis with a
160. Hickok LR, Burry KA, Cohen NL, et al. Medical treatment of endometriosis: a comparison of the suppressive effects of danazol and nafarelin on reproductive hormones. Fertil Steril 1991;56(4):622-7
161. Kennedy SH, Williams IA, Brodribb J, et al. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990;53(6):998-1003 (Pubitemid 20208962)
162. Tummon IS, Pepping ME, Binor Z, et al. A randomized, prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertil Steril 1989;51(3):390-4 (Pubitemid 19083647)
163. Tummon IS, Ali A, Pepping ME, et al. Bone mineral density in women with endometriosis before and during ovarian suppression with gonadotropin-releasing hormone agonists or danazol. Fertil Steril 1988;49(5):792-6
164. Friedman AJ, Hornstein MD. Gonadotropin-releasing hormone agonist plus estrogen-progestin "add-back" therapy for endometriosis-related pelvic pain. Fertil Steril 1993;60(2):236-41 (Pubitemid 23228151)
165. Hornstein MD, Surrey ES, Weisberg GW, et al. Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. Obstet Gynecol 1998;91(1):16-24 (Pubitemid 28042326)
166. Surrey ES, Hornstein MD. Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet Gynecol 2002;99(5 Pt 1):709-19 (Pubitemid 34442445)
167. Seracchioli R, Mabrouk M, Frasca C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril 2010;93(1):52-6
168. Vercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol 2008;198(5):504; e1-5
169. Mizutani T, Nishiyama S, Amakawa I, et al. Danazol concentrations in ovary, uterus, and serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository. Fertil Steril 1995;63(6):1184-9
170. Kim YA, Kim MR, Lee JH, et al. Gonadotropin-releasing hormone agonist reduces aromatase cytochrome P450 and cyclooxygenase-2 in ovarian endometrioma and eutopic endometrium of patients with endometriosis. Gynecol Obstet Invest 2009;68(2):73-81
171. Tokushige N, Markham R, Russell P, et al. Effect of progestogens and combined oral contraceptives on nerve fibers in peritoneal endometriosis. Fertil Steril 2009;92(4):1234-9
172. Abushahin F, Goldman KN, Barbieri E, et al. Aromatase inhibition for refractory endometriosis-related chronic pelvic pain. Fertil Steril 2011;96(4):939-42